Armata Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US04216R1023
USD
5.94
-0.05 (-0.83%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Vaxart, Inc.
Century Therapeutics, Inc.
Aadi Bioscience, Inc.
Sonnet BioTherapeutics Holdings, Inc.
Armata Pharmaceuticals, Inc.
Sangamo Therapeutics, Inc.
Galectin Therapeutics, Inc.
Theseus Pharmaceuticals, Inc.
Greenwich LifeSciences, Inc.
PepGen Inc.
Omega Therapeutics, Inc.
Why is Armata Pharmaceuticals, Inc. ?
Icon
Unrated Stock - No Analysis Available
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
50.96%
EBIT Growth (5y)
-25.24%
EBIT to Interest (avg)
-20.19
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.78
Sales to Capital Employed (avg)
0.08
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
2.15%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.33
EV to EBIT
-4.14
EV to EBITDA
-4.28
EV to Capital Employed
4.00
EV to Sales
35.59
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-96.72%
ROE (Latest)
Negative BV
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company
NET SALES(HY)

At USD 2.66 MM has Grown at 175.36%

OPERATING CASH FLOW(Y)

Highest at USD -31.58 MM

RAW MATERIAL COST(Y)

Fallen by -8,313% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 4.03 times

OPERATING PROFIT(Q)

Highest at USD -6.48 MM

PRE-TAX PROFIT(Q)

Highest at USD -10.54 MM

NET PROFIT(Q)

Highest at USD -10.54 MM

-9What is not working for the Company
CASH AND EQV(HY)

Lowest at USD 16.02 MM

INTEREST(Q)

Highest at USD 3.81 MM

EPS(Q)

Lowest at USD -0.45

Here's what is working for Armata Pharmaceuticals, Inc.
Net Sales
At USD 2.66 MM has Grown at 175.36%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (USD MM)

Operating Cash Flow
Highest at USD -31.58 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit
Highest at USD -6.48 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit
Highest at USD -10.54 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit
Highest at USD -10.54 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

Debtors Turnover Ratio
Highest at 4.03 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -8,313% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Armata Pharmaceuticals, Inc.
Interest
Highest at USD 3.81 MM
in the last five periods and Increased by 5.72% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

EPS
Lowest at USD -0.45
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Cash and Eqv
Lowest at USD 16.02 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents